TY - JOUR
T1 - Global access of patients with kidney disease to health technologies and medications
T2 - findings from the Global Kidney Health Atlas project
AU - Htay, Htay
AU - Alrukhaimi, Mona
AU - Ashuntantang, Gloria E.
AU - Bello, Aminu K.
AU - Bellorin-Font, Ezequiel
AU - Benghanem Gharbi, Mohammed
AU - Braam, Branko
AU - Feehally, John
AU - Harris, David C.
AU - Jha, Vivekanand
AU - Jindal, Kailash
AU - Kalantar-Zadeh, Kamyar
AU - Kazancioglu, Rumeyza
AU - Kerr, Peter G.
AU - Levin, Adeera
AU - Lunney, Meaghan
AU - Okpechi, Ikechi G.
AU - Olah, Michelle E.
AU - Olanrewaju, Timothy Olusegun
AU - Osman, Mohamed A.
AU - Parpia, Yasin
AU - Perl, Jeffrey
AU - Qarni, Bilal
AU - Rashid, Harun Ur
AU - Rateb, Ahmed
AU - Rondeau, Eric
AU - Salako, Babatunde Lawal
AU - Sola, Laura
AU - Tchokhonelidze, Irma
AU - Tonelli, Marcello
AU - Wiebe, Natasha
AU - Wirzba, Isaac
AU - Yang, Chih Wei
AU - Ye, Feng
AU - Zemchenkov, Alexander
AU - Zhao, Ming hui
AU - Johnson, David W.
N1 - Publisher Copyright:
© 2017
PY - 2018/2
Y1 - 2018/2
N2 - Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population, providing data on this domain. Most countries were unable to access eGFR and albuminuria in their primary care settings. Only one-third of low-income countries (LICs) were able to measure serum creatinine and none were able to access eGFR or quantify proteinuria. The ability to monitor diabetes mellitus through serum glucose and glycated hemoglobin measurements was suboptimal. Pathology services were rarely available in tertiary care in LICs (12%) and lower middle-income countries (45%). While acute and chronic hemodialysis services were available in almost all countries, acute and chronic peritoneal dialysis services were rarely available in LICs (18% and 29%, respectively). Kidney transplantation was available in 79% of countries overall and in 12% of LICs. While over one-half of all countries publicly funded RRT and kidney medications with or without copayment, this was less common in LICs and lower middle-income countries. In conclusion, this study demonstrated significant gaps in services for kidney care and funding that were most apparent in LICs and lower middle-income countries.
AB - Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population, providing data on this domain. Most countries were unable to access eGFR and albuminuria in their primary care settings. Only one-third of low-income countries (LICs) were able to measure serum creatinine and none were able to access eGFR or quantify proteinuria. The ability to monitor diabetes mellitus through serum glucose and glycated hemoglobin measurements was suboptimal. Pathology services were rarely available in tertiary care in LICs (12%) and lower middle-income countries (45%). While acute and chronic hemodialysis services were available in almost all countries, acute and chronic peritoneal dialysis services were rarely available in LICs (18% and 29%, respectively). Kidney transplantation was available in 79% of countries overall and in 12% of LICs. While over one-half of all countries publicly funded RRT and kidney medications with or without copayment, this was less common in LICs and lower middle-income countries. In conclusion, this study demonstrated significant gaps in services for kidney care and funding that were most apparent in LICs and lower middle-income countries.
KW - acute kidney injury and chronic kidney disease care
KW - funding for health care
KW - funding for medications
KW - global health care
KW - health care service provision
KW - renal replacement therapy
UR - http://www.scopus.com/inward/record.url?scp=85041684684&partnerID=8YFLogxK
U2 - 10.1016/j.kisu.2017.10.010
DO - 10.1016/j.kisu.2017.10.010
M3 - 文献综述
AN - SCOPUS:85041684684
SN - 2157-1724
VL - 8
SP - 64
EP - 73
JO - Kidney International Supplements
JF - Kidney International Supplements
IS - 2
ER -